Introduction
============

Spinal muscular atrophy and amyotrophic lateral sclerosis are two devastating neurological conditions with the common pathological hallmark of motor neuron degeneration, ultimately leading to muscle wasting and death. While etiology, age of onset, progression, and survival outcomes can drastically differ between the diseases, they share a number mechanistic parallels; thus, experimental and clinical insights into the one disorder may prove useful for the other.

It is an exciting time for the SMA community as the first treatment, an ASO gene therapy called nusinersen, was approved in the US by the FDA on 23rd December, 2016. Nusinersen subsequently received marketing authorisation in the EU from the EMA in June, 2017. This starkly contrasts with the situation for ALS, where clinically viable gene therapies are currently non-existent, while recent trials of chemically diverse drugs have failed to live up to expectations piqued by mouse experiments. Although there are numerous complications in treating ALS that do not pertain to SMA, a number of fundamental lessons have been learnt from the gamut of pre-clinical research and clinical trials of SMA gene therapies that could prove useful in galvanizing a targeted approach to ALS gene therapy design and development.

In this review, we will first provide introductions to SMA, ALS, and commonalities between the two, and follow this with an overview of gene therapies tested in clinical trials for both diseases. We use the term gene therapy to encompass both virus-mediated gene transfer and ASO gene targeting. Rather than provide an exhaustive review of all SMA and ALS gene therapy research, which has been collectively well covered ([@B66]; [@B191]; [@B183]; [@B231]; [@B239]), we will then outline some of the major issues that SMA gene therapy has encountered, try to distil key, emergent concepts, and frame this in the context of ALS in order to provide possible future experimental directions.

Diseases of Motor Neurons: Genetics, Classifications, And Mechanisms
====================================================================

Spinal Muscular Atrophy
-----------------------

Spinal muscular atrophy (SMA) is a monogenic neuromuscular disorder affecting ≈1 in 8,500--12,500 newborns, and is the most common genetic cause of infant mortality ([@B281],[@B282]). Patients present with severe muscle weakness and atrophy, predominantly in proximal (e.g., trunk) muscles, due to degeneration of LMNs of the spinal cord ventral horn. Pathology in additional cells and tissues can be observed in more severe manifestations of the disease, which has considerable implications for treatment ([@B100]). SMA is caused by reduced levels of SMN protein ([@B142]), which is found in the nucleus and cytoplasm of almost all cells, and plays a vital, canonical, housekeeping role in spliceosome assembly ([@B72]; [@B152]; [@B204]), amongst other functions ([@B241]). Specifically, as part of the multi-protein SMN complex, SMN directs the efficient cytoplasmic assemblage of small nuclear RNAs (snRNAs) with Sm protein rings leading to the formation of small nuclear ribonucleoproteins (snRNPs) ([@B95]). After nuclear-import, snRNPs function in the catalytic removal of introns from pre-mRNA transcripts in the process of splicing ([@B204]). Despite having a good understanding of this and other functions of SMN, the precise cause of the largely selective LMN death remains to be fully resolved. It is likely that a combination of multiple mechanisms account for this vulnerability, including mis-splicing of LMN-specific genes, SMN levels being lower in LMNs than other cell types, and disturbance of a possible non-canonical, LMN-specific SMN function (**Figure [1A](#F1){ref-type="fig"}**) ([@B259]; [@B120]; [@B267]).

![Spinal muscular atrophy mechanisms and genetics. **(A)** Multiple hypothetical mechanisms have been suggested to cause or contribute to the selective LMN degeneration of SMA, the three most plausible of which are that: \#1 SMN reduction impairs splicing fidelity of a LMN-specific gene(s). E, exon; I, intron; \#2 less SMN is available in LMNs than other cells due to a negative feedback loop, more prominent in LMNs, in which low SMN levels impair further *SMN2* exon 7 inclusion (see **B**) exacerbating SMN reduction. Δ7, truncated *SMN* mRNA; FL, full-length *SMN* mRNA; FL-SMN, full-length SMN protein; snRNPs, small nuclear ribonucleoproteins; and \#3 a non-canonical, LMN-specific function of SMN is perturbed, for instance anterograde axonal transport of mRNA. **(B)** A single copy of *SMN1* produces enough SMN protein for motor neurons to thrive and for SMA disease carriers to remain healthy. Due to a single base pair distinction (C-to-T transition in exon 7), exon 7 is mis-spliced out of ≈90% of *SMN2* transcripts, resulting in a truncated, less stable, and only partially functional protein. This figure has been adapted from *Neuromuscular Disorders*, 23, [@B244] Spinal muscular atrophy at the crossroads of basic science and therapy, 96, Copyright (2013), with permission from Elsevier.](fnmol-10-00405-g001){#F1}

Survival motor neuron is encoded by two almost identical genes, *SMN1* and its paralogue *SMN2* (**Figure [1B](#F1){ref-type="fig"}**) ([@B142]). A single functioning *SMN1* allele produces sufficient protein for LMNs to remain healthy -- as demonstrated by the ≈1 in 40--60 people with one functional copy of *SMN1* (i.e., SMA carriers) showing no clinical phenotype. However, due to a single nucleotide distinction (synonymous C-to-T alteration 6 nucleotides into exon 7), exon 7 of *SMN2* is aberrantly spliced ≈90% of the time (creating truncated, non-functional SMNΔ7 protein) and is therefore capable of producing only ≈10% of the full-length SMN made by *SMN1* (**Figure [1B](#F1){ref-type="fig"}**) ([@B155]; [@B180]). Thus, when protein production from *SMN1* is impaired, as it is in SMA patients, *SMN2* can only partially compensate. SMN is highly conserved throughout evolution, permitting modeling of reduced SMN function in diverse organisms ([@B93]; [@B202]; [@B61]); however, all models naturally only possess an ortholog of *SMN1*, but not *SMN2*. To better mimic disease genetics, many transgenic mice have been engineered to express diminished SMN levels ([@B243]), the most frequently used being the SMNΔ7 mouse, which combines human *SMN2* and *SMN*Δ*7* transgenes on a null *Smn* background ([@B139]). Relative genomic instability of the region (5q13) is believed to be the reason for the recent evolutionary duplication of the *SMN* locus ([@B222]), and may also account for there being considerable variability in *SMN2* copy number within the population. The number of *SMN2* genes a patient with SMA possesses has important ramifications for disease severity, as more *SMN2* copies can produce more SMN, which correlates with diminished symptom severity ([@B143]). Although not predictive at the individual level, in a population, *SMN2* copy number thus inversely correlates with SMA severity ([@B167]), which is categorised into four principal post-natal types (I-IV) based on age of onset and motor milestones achieved ([@B184]).

Manifesting at or before 6 months and radically limiting life expectancy (\<2 years), type I SMA (a.k.a. Werdnig-Hoffmann disease) is the most severe and frequently diagnosed form of SMA, and prevents children from ever being able to sit unaided. Infant death is usually caused by respiratory complications, although with specialized care, lifespan can be artificially extended for long periods. Type II SMA (Intermediate/Dubowitz Syndrome) presents between 7 and 18 months, permits unaided sitting but not walking, and has survival probabilities of ≈93% and ≈52% at 20 and 40 years, respectively ([@B65]). Type III SMA (Kugelberg-Welander disease) limits motor function and has an onset \> 18 months, but before adolescence, while type IV SMA (adult-onset) typically manifests in the second or third decade of life with mild-to-moderate muscle weakness, but generally no respiratory issues.

Amyotrophic Lateral Sclerosis
-----------------------------

With a lifetime risk of ≈1 in 400 ([@B8]), ALS, also called MND and Lou Gehrig's disease, is a fatal, progressive, mostly adult-onset disorder of both LMNs and UMNs. Neurodegeneration is observed in the cortex, corticospinal tracts, brainstem, and spinal ventral horn neurons and is accompanied by neuroinflammation ([@B35]). Starting focally and spreading, this causes major symptoms of muscle weakness and fasciculations with subsequent atrophy, leading to death usually through respiratory failure within 3 years of diagnosis ([@B45]). ALS also shares neuropathological and genetic features with FTD ([@B182]; [@B189]; [@B278]), with approximately half of ALS patients showing some level of cognitive impairment ([@B221]). This has led to ALS and FTD being considered as part of the same clinicopathological spectrum ([@B148]). ALS patients display considerable symptom heterogeneity inclusive of age, site of disease onset, the rate and pattern of spread, and relative LMN/UMN involvement ([@B129]). ALS can therefore be sub-categorized based on several clinical and neuropathological criteria ([@B6]; [@B19]). Given this variability, the ALS diagnosis is challenging, particularly during early disease stages ([@B39]). The mean time from first noticeable symptom to clinical diagnosis is consequently (≈1 year). Contributing to this delay, no diagnostic or prognostic biomarkers are yet in regular clinical use for ALS, which also impacts the assessment of therapeutic efficacy in patient trials ([@B225]). Nevertheless, a number of prospective biomarkers have recently been identified, including the neurotrophin receptor p75^NTR^ extracellular domain in urine ([@B237]) and neurofilament chains in plasma ([@B156]) and CSF ([@B195]).

ALS has traditionally been classified into clinically indistinguishable sporadic (sALS) and familial (fALS) forms; sALS occurs without family history of the disease and represents the majority of cases (≈90%), whereas fALS contributes ≈10% of patients and is genetically inherited, predominantly in an autosomal, dominant fashion. The pathological and clinical variability of the disease has led to the idea that, in addition to being on a continuum with FTD, ALS itself may not be a single disorder, but a syndrome ([@B271]). Consistent with this, aberrations in over 25 genetic loci have been reproducibly linked with the ALS phenotype ([@B35]), with new genes constantly being identified ([@B80]; [@B34]; [@B160]). The four most common mutations are large, intronic, hexanucleotide repeat (G~4~C~2~) expansions in *chromosome 9 open reading frame 72* (*C9orf72*) ([@B53]; [@B218]), and dominant mutations in *superoxide dismutase 1* (*SOD1*) ([@B224]), *transactive-region DNA binding protein* (*TARDBP* encoding TDP-43) ([@B247]), and *fused in sarcoma* (*FUS*, a.k.a. *translocated in liposarcoma*, *TLS*) ([@B136]; [@B279]). Mutations in *C9orf72* are the most common genetic cause of ALS hitherto identified, accounting for ≈40% of fALS and ≈7% of sALS (in populations of European ancestry) ([@B217]). The exact function of the encoded protein remains unclear, but it appears that it may be important in membrane trafficking and autophagy ([@B188]). Encoding a Cu/Zn dismutase enzyme that provides defense against toxic superoxide free radicals, *SOD1* was the first gene linked to ALS ([@B224]), and its mutation is responsible for ≈12% and ≈1% of fALS and sALS patients, respectively ([@B217]). As a consequence of its early identification and the rapid generation of the SOD1^G93A^ mouse model ([@B96]), research into *SOD1* has shaped much of the ALS research landscape. Nevertheless, many other cellular and animal models are now available for different genetic forms of the disease ([@B274]). *TARDBP* and *FUS* encode nucleic acid-binding proteins that predominantly reside in the nucleus, and are involved in multiple aspects of RNA processing, such as transcription and splicing. Mutations in these two genes each account for ≈4% of fALS and ≈1% of sALS patients ([@B217]). Despite significant progress in our understanding of the molecular pathogenesis linked to these four genes, it has not been fully resolved as to whether pathology is solely caused by a toxic gain-of-function or whether there are also loss-of-function effects ([@B140]; [@B37]; [@B232]; [@B176]).

Causative genetic mutations have been identified in only ≈68% and ≈11% of fALS and sALS patients, respectively ([@B217]). This lack of an obvious genetic cause in most ALS patients, along with incomplete penetrance in several fALS pedigrees ([@B47]; [@B80]), suggests that ALS may most frequently arise from additive effects of an assortment of predispositions and insults ([@B6]). Indeed, rare variants in many other genes have been identified as ALS risk factors ([@B276]), as have particular environmental stimuli ([@B164]). Moreover, twin studies indicate that sALS heritability in the absence of a family history of the disease is still ≈60% ([@B5]). Together, these data indicate that ALS may develop through a multi-step process in which aging is a critical component ([@B4]), involving varying degrees of heritability and diverse, but inter-related, functional pathways that, upon dysregulation, yield motor neuron degeneration ([@B271]). This makes the strict fALS/sALS distinction an artificial dichotomy ([@B255]), and presents obvious and considerable hurdles for the identification and development of viable therapeutic strategies for the disease.

Intrinsic motor neuron defects and non-cell autonomous toxicities in associated cell types (e.g., glia, interneurons) contribute to ALS ([@B116]; [@B212]; [@B210]), but similar to SMA, the exact mechanisms underpinning motor neuron death, and their relative vulnerability-resistance axis ([@B190]), remain to be elucidated. Nevertheless, given the known functions of major ALS genes, altered RNA processing, nuclear protein mishandling/protein quality control, and impaired cytoskeletal dynamics appear to be three inter-related central themes ([@B17]; [@B35]). Congruously, the vast majority of both sALS and fALS patients display cytoplasmic depositions of aggregated proteins, the main component of which is TDP-43 ([@B189]), albeit with varied cellular distributions ([@B9]). However, these inclusions conspicuously lack TDP-43 in *SOD1*-linked ([@B161]) and *FUS*-linked ([@B279]) ALS. Additional defects in diverse cellular processes have been implicated in ALS including excitotoxicity, oxidative stress, altered oligodendrocyte function, axonal transport defects, mitochondrial malfunction, and neurotrophic factor deficits (reviewed in [@B129]; [@B256]). It remains unclear as to which, if any, of these phenomena play a primary role in disease pathogenesis, rather than simply being non-specific consequences of a dysfunctional system. Moreover, it should be noted that most of these pathologies were identified using SOD1^G93A^ mice, which have their limitations for modeling all forms of ALS ([@B129]; [@B271]). To overcome this, numerous transgenic mouse models of ALS have been developed ([@B274]), and strict guidelines for their use in pre-clinical therapeutic trials have been created to limit irreproducibility ([@B158]).

SMA and ALS: A Common Mechanism?
--------------------------------

SMA and ALS share a propensity for LMN degeneration leading to muscle wasting and atrophy. A number of key cellular and molecular parallels between the two diseases have also been reported ([@B40]; [@B83]; [@B107]). The causative gene in SMA encodes a widely expressed, multi-functional protein important for fundamental cellular processes including pre-mRNA splicing ([@B72]; [@B152]; [@B204]), transcription ([@B203]), and mRNA transport and stability ([@B227]; [@B300]). While the importance of protein quality control to ALS should not be underestimated, some of the major genetic contributors to the disease, perhaps with the exception of C9ORF72, are also found ubiquitously and perform similar functions vital to RNA processing and maturation ([@B17]). For instance, both TDP-43 and FUS are involved in splicing ([@B303]; [@B207]) and transcription ([@B272]), and, along with SOD1, are thought to be important for the transport and stability of mRNA ([@B81]; [@B157]; [@B250]). Recently, dominant mutations in *T-cell restricted intracellular antigen 1* (*TIA1*), which is an RNA-binding protein involved in *SMN2* exon 7 splicing ([@B240]), were shown to play a causative role in ALS ([@B160]), while *TIA1* knockout modifies phenotypes of mild male SMA mice ([@B109]). Furthermore, wild-type TDP-43 and FUS interact with SMN ([@B286]; [@B297]; [@B94]; [@B253]), and all three proteins have been implicated in the formation of stress granules ([@B114]; [@B10]; [@B48]), as has C9ORF72 ([@B162]).

Comparable in structure to stress granules, Gemini of Cajal bodies (a.k.a. gems) are membrane-free, nuclear conglomerates of SMN and associated proteins ([@B151]), the number of which correlates with SMN availability and is thus inversely related to SMA severity ([@B143]; [@B68]). Numerous studies have shown that gem distribution/number is also affected in SOD1-, FUS-, and TDP-43-associated ALS patient tissue, mice, and cellular models ([@B236]; [@B87]; [@B124]; [@B297]; [@B118]; [@B266]; [@B253]), although this pattern was not observed in sALS patient fibroblasts ([@B125]). Nonetheless, SMN protein levels are reduced in sALS patient spinal cords ([@B268]) and pre-symptomatically in SOD1^G93A^ mouse spinal cords, while a 50% reduction in SMN exacerbates the SOD1^G93A^ phenotype ([@B270]). Furthermore, one study showed that ALS patients on average possess fewer *SMN2* copies, while having one *SMN1* copy is associated with increased ALS susceptibility ([@B280]), although this link is not straightforward ([@B27]; [@B50]; [@B290]). Nevertheless, SMN upregulation protects against mutant SOD1-induced cell death in an immortalized motor neuronal cell line (NSC-34) ([@B305]), rescues mutant FUS-mediated axonal defects in primary cortical neurons ([@B94]), and can improve survival of iPSC-derived motor neurons differentiated from SOD1 and TDP-43 ALS patient fibroblasts ([@B223]). Moreover, neuronal SMN overexpression aids motor neuron survival and delays symptom onset in SOD1^G85A^, SOD1^G93A^, and TDP-43^A315T^ mice ([@B124]; [@B268]; [@B205]). Survival of both SOD1 models was unaffected, but female TDP-43 mice displayed a significant extension. SMN may in fact serve as a general survival factor for motor neurons, as it is required to facilitate neuromuscular regeneration post-sciatic nerve crush in adult mice ([@B123]). In addition, low SMN levels in healthy iPSC-derived motor neurons correlate with greater cell death, and SMN upregulation promotes increased survival of control motor, but not cortical, neurons ([@B223]).

These commonalities between SMA and ALS suggest that a shared mechanism could underlie at least certain aspects of the two diseases. Perhaps the most likely cause of the link is sequestration of SMN and/or splicing factors into cytoplasmic inclusions by mutant ALS gene products, resulting in defective RNA homeostasis. Indeed, ALS-associated mutations in FUS can enhance its association with SMN and impinge upon its axonal localization ([@B94]; [@B253]). Additionally, mutant FUS and *C9orf72* expansion can affect splicing factor distribution ([@B86]; [@B141]; [@B181]; [@B299]; [@B215]), as can homozygous overexpression of human wild-type FUS in mice ([@B173]). Widespread splicing defects are unlikely to account for the motor neuron selectivity observed in SMA ([@B18]); however, the early and specific mis-splicing of a few crucial motor neuron-expressed genes may be particularly relevant to disease pathogenesis ([@B301]; [@B242]). Splicing impairments have also been reported in ALS models and patient tissue ([@B41]; [@B49]); it is thus plausible that early splicing perturbations in a common set of critical genes could explain some of the shared pathomechanisms of SMA and ALS. Indeed, considerable overlap in alternative splicing events between SMA models and human FUS-expressing mice were recently reported, including in a number of ALS-pertinent genes ([@B173]). These discoveries and the mechanistic intersection of ALS with SMA, suggest that gene therapy strategies able to augment SMN levels may be beneficial to both fALS and sALS patients, perhaps not in isolation, but as part of a combinatorial approach.

Clinical Gene Therapy for Motor Neuron Diseases
===============================================

SMA: SMN Restoration Is Key
---------------------------

The genetic lesion underlying SMA causes diminished SMN protein levels; in theory, treatment is thus simple -- replenish SMN. Small molecule, *SMN2* splice-modifying drugs, such as RG7916 (Roche) and LMI070 (Novartis), that augment SMN and SMN-independent, neuroprotection strategies are being pursued ([@B233]), but *SMN* gene therapies are currently proving more clinically promising. In the last decade, we have rapidly transitioned from several early ineffective SMA patient trials ([@B82]), to the recent regulatory approval of nusinersen for the treatment of SMA types I-IV.

Nusinersen (a.k.a. Spinraza, IONIS-SMN~Rx~, ISIS-SMN~Rx~, ISIS 396443, and ASO-10-27) is an ASO developed through work of numerous laboratories and a collaboration between Biogen Idec and Ionis Pharmaceuticals (formerly Isis Pharmaceuticals). ASOs are short (15--25 nucleotides), synthetic, single-stranded DNA or RNA sequences that specifically bind to target pre-mRNA or mRNA sequences, impacting gene expression. ASOs that specifically modulate splicing are also called SSOs. Importantly for diseases affecting the nervous system, ASOs distribute widely when injected into the CSF, do not require carrier molecules, and have relatively long half-lives ([@B84]). Nusinersen, which is delivered via single intrathecal injections directly into the CSF (i.e., by lumbar puncture) ([@B46]; [@B99]), is a 2′-*O*-(2-methoxyethyl) modified ASO complementary to the ISS-N1 found in intron 7 of *SMN2* pre-mRNA ([@B238]; [@B113]). Specific ASO/pre-mRNA hybridisation restricts exon 7 mis-splicing, thereby increasing the amount of functional SMN made by *SMN2* (**Figure [2A](#F2){ref-type="fig"}**). A considerable amount of work in SMA mice provided substantial evidence for *in vivo* efficacy of nusinersen ([@B239]), leading to a series of stratified clinical trials ([@B46]; [@B70], [@B71]). A pre-specified interim analysis from a randomized, double-blind, sham procedure-controlled phase III trial in SMA type I patients called ENDEAR (ClinicalTrials.gov Identifier: NCT02193074), provided enough evidence in mid-2016 that nusinersen caused statistically significant improvements in motor function ([@B71]), prompting submission to the FDA of the new drug application. Interim analyses from a second phase III trial with type II SMA patients called CHERISH (NCT02292537) and an open-label study in pre-symptomatic infants named NURTURE (NCT02386553) have also proven encouraging.

![Antisense oligonucleotide targeting of *SMN2* splicing and *SOD1* translation. **(A)** Nusinersen is a SSO complementary to an intronic sequence in *SMN2* called ISS-N1, which is the main inhibitory element for exon 7 splicing. Hybridisation of nusinersen to ISS-N1 within pre-mRNA causes more frequent inclusion of exon 7 in mature *SMN2* transcripts, leading to an increase in the production of full-length SMN protein. Nusinersen is FDA- and EMA- approved for the treatment of SMA. **(B)** IONIS-SOD1~Rx~ specifically targets a 20 nucleotide-long sequence within exon 1 of *SOD1*, resulting in binding to both pre-mRNA and mature RNA causing inhibition of wild-type and mutant *SOD1* expression. ALS patients are currently being recruited for a phase Ib/IIa trial of IONIS-SOD1~Rx~.](fnmol-10-00405-g002){#F2}

A second gene therapy called AVXS-101 (a.k.a. scAAV9.CB.SMN and ChariSMA), which delivers the *SMN1* gene using non-replicating self-complementary adeno-associated virus serotype 9 (scAAV9), has also shown significant pre-clinical potential ([@B183]). A major advantage of this therapy over nusinersen is that AAV9 can cross the BBB in mice, cats, and non-human primates, permitting intravenous delivery ([@B60]; [@B75]; [@B230]). Moreover, AAV9 displays neuronal tropism and can mediate stable, long-term expression with a single administration, which is important given immunogenicity issues associated with viruses ([@B154]). This contrasts with the multiple, invasive intrathecal injections of nusinersen, which can have adverse side effects ([@B99]). Marketed by AveXis, AVXS-101 has completed testing in type I SMA patients in an open-label, dose-escalation phase I clinical trial (NCT02122952). The treatment is safe and well tolerated, and caused improvements in survival, attainment of motor milestones, and motor function when compared with historical SMA type I cohorts ([@B168]). Two further open-label phase III trials with type I patients in the US and EU are planned. *SMN1* expression is driven by a hybrid cytomegalovirus enhancer/chicken β-actin (CAG) promoter, and AVXS-101 is being injected intravenously.

ALS: A Gene Therapy on the Horizon?
-----------------------------------

No drugs are currently being tested in late-stage clinical trials for ALS, and until recently, the only FDA-/EMA-approved drug for the disease was the orally available Riluzole, which prolongs patient survival by ≈3 months ([@B22]). Riluzole can influence ion channel function, neurotransmission, and growth factor secretion, but inhibition of glutamate release from pre-synaptic nerve terminals counteracting motor neuron excitotoxicity appears to be the most disease-relevant benefit ([@B22]). In May 2017, the FDA surprisingly approved Edaravone (a.k.a. MCI-186 and Radicava), which is a free radical scavenger shown to modestly slow symptom progression in SOD1^G93A^ mice ([@B119]). In an open-label phase II study without comparator arm involving 19 ALS patients, intravenous administration of Edaravone was shown to be safe and reduce oxidative stress ([@B298]); however, in a subsequent double-blind, placebo-controlled study, drug efficacy was not demonstrated ([@B1]). Nevertheless, a phase III trial with narrow inclusion criteria showed Edaravone modestly delayed disease progression in a limited subset of ALS patients ([@B294]). Edaravone is unlikely to be effective in a wider ALS population and there is a sizeable administration burden, limiting excitement for the drug ([@B102]). Palliative care incorporating dietary and respiratory support, speech and language therapy, and specialist physiotherapy can also improve survival in ALS ([@B165]), and provides arguably a greater benefit to quality of life than current pharmaceutical intervention ([@B103]).

In over 20 years since the approval of Riluzole, more than 20 additional compounds have been tested in over 50 randomized, controlled trials, involving in excess of 13,000 ALS patients, with little clinical success ([@B174]; [@B206]). Consistent with ALS complexity, the tested drugs possess a broad range of proposed mechanisms of action, including anti-inflammation and anti-oxidation. Rather than targeting the underlying genetics, these compounds were trialled for their ability to support the ailing ALS nervous system and restrict the insidious progression of disease. These unsuccessful therapeutics include three neurotrophic factors delivered as recombinant proteins - BDNF, CNTF, and insulin-like growth factor-1 (IGF-1) ([@B15]). Also known as neurotrophins, neurotrophic factors are target-secreted (e.g., from muscles) proteins essential for the growth, development and survival of several nerve types, including motor neurons ([@B115]). Delivering neurotrophins has been pursued as a therapy for ALS because their expression can decline with time in models and patients ([@B132]). While injection of recombinant proteins is not gene therapy *per se*, when adapted for delivery by viruses, these and other neurotrophic factors have shown promising results in pre-clinical ALS models ([@B106]; [@B191]) (**Table [1](#T1){ref-type="table"}**). Additionally, intramuscular injections of plasmids encoding multiple isoforms of hepatocyte growth factor (HGF, drug named VM202) or a transcription factor able to increase expression of vascular endothelial growth factor (VEGF, drug named SB-509) have been trialled in ALS patients ([@B231]). Both plasmids had favorable safety profiles in phase I/II studies (VM202, NCT02039401 and SB-509, NCT00748501) ([@B251]), but whether these drugs will be tested further remains unclear ([@B231]).

###### 

Virus-mediated, neuroprotection gene therapies tested in animal models of ALS.

  Delivery                      Virus-promoter-transgene                                                   Age at injection   Major findings                                                                                                                                                                                                                        Animal model             Reference        
  ----------------------------- -------------------------------------------------------------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ---------------- --
  **GDNF**                                                                                                                                                                                                                                                                                                                                                                                                    
  T/p: MPCs into GC             Rv-PGK1-GDNF (*ex vivo*)                                                   P42                Preserved MN size/number and muscle weight, resulting in improved motor function and extended survival.                                                                                                                               SOD1^G93A^ mouse         [@B177]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/M: GC, PS, Q, TA            Ad-CMV-GDNF                                                                P5--7              Preserved MNs, improved motor function, delayed disease onset, and extended survival. No significant benefit in CMAP.                                                                                                                 SOD1^G93A^ mouse         [@B3]            
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/M: GC, TB                   AAV2-CMV-GDNF                                                              P56                Delayed disease onset, reduced muscle atrophy, preserved MNs, improved motor function, and extended survival.                                                                                                                         SOD1^G93A^ mouse         [@B287]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  T/p: hNPCs into lumbar SC     LV-PGK1-GDNF (*ex vivo*)                                                   P100               Robust GDNF expression at end-stage and upregulation of ChAT in the ventral horn, but no significant changes in disease observed.                                                                                                     SOD1^G93A^ rat           [@B130]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  T/p: hMSCs into DT, TA, TB    LV-PGK1-GDNF (*ex vivo*)                                                   P80 (F)            Control and GDNF hMSCs improved NMJ innervation and preserved MNs. GDNF hMSCs extended survival.                                                                                                                                      SOD1^G93A^ rat strains   [@B254]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  T/p: MPCs into GC             CMV-GDNF, -VEGF, -IGF-1, and/or -BDNF (*ex vivo*)                          P90/P104 /P118     Combined MPC delivery synergistically delayed disease onset, improved motor function and NMJ innervation, and extended survival.                                                                                                      SOD1^G93A^ mouse         [@B51]           
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/V: tail                     AAV9-CAG-GDNF                                                              ∼P25               Brain, SC, and limb-muscle GDNF expression. Preserved MNs, increased weight gain and motor function in FL, but not HL.                                                                                                                SOD1^G93A^ rat           [@B257]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  **IGF-1**                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/M: InC, Q                   AAV2-CMV-IFG-1, or -GDNF                                                   P60/P90            IGF-1 delayed disease onset and rate of disease progression, even when delivered symptomatically (P90). GDNF only delayed disease onset.                                                                                              SOD1^G93A^ mouse         [@B126]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/S: lumbar                   AAV2-CAG-IGF-1                                                             P60                Preserved MNs and improved motor function, but no difference in microgliosis. Delayed disease onset and extended survival in M.                                                                                                       SOD1^G93A^ mouse         [@B145]          
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/C                           AAV1-, or AAV2-CMV-IGF-1                                                   P88--90            Preserved MNs, improved motor function, reduced astrogliosis/microgliosis, and extended survival. AAV1 caused better cervical MN preservation, but there was no survival difference between serotypes.                                SOD1^G93A^ mouse         [@B57]           
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/S: cervical                 AAV2-CAG-IGF-1                                                             P80                Preserved MNs. Improved motor function in M. No change in disease onset, disease progression, or survival.                                                                                                                            SOD1^G93A^ rat           [@B79]           
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/CV                          AAV4-CMV-IGF-1, and/or -VEGF-165                                           P80--90            Individually, both improved motor function, and extended survival. No additive effect of combined treatment.                                                                                                                          SOD1^G93A^ mouse         [@B58]           
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/M: InC, Q                   AAV9-CAG-IGF-2                                                             P80                Preserved MNs, improved motor function, induced nerve regeneration, and extended survival.                                                                                                                                            SOD1^G93A^ mouse         [@B7]            
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/M: GC, InC, TA, TB          LV-αCAR-CMV-IGF-1 (MN-specific), or LV-VSV-G-CMV-IGF-1 (muscle-specific)   P28                MN-specific: preserved MNs, improved motor function, delayed disease onset, and extended survival. Muscle-specific: delayed disease onset and improved motor function, but not as well as MN-specific. Gender differences observed.   SOD1^G93A^ mouse         [@B63]           
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                              
  I/M -- Ab, FL, HL, InC, Ma    scAAV9-CMV-IGF-1                                                           P60/P90            Delayed disease onset, preserved MNs, improved motor function, and extended survival.                                                                                                                                                 SOD1^G93A^ mouse         [@B147]          
  **VEGF**                                                                                                                                                                                                                                                                                                                                                                                                    
  I/M: D, F, GC, InC, T         LV(EIAV)-VEGF-165, or GDNF                                                 P21/P90            VEGF-165 delayed disease onset, reserved MNs, and extended survival, even when delivered symptomatically (P90). GDNF had little impact on disease phenotypes.                                                                         SOD1^G93A^ mouse         [@B14]           
  I/C, I/CV, or I/V: jugular    ssAAV1-PGK1-VEGF, or scAAV9-PGK1-VEGF                                      P2/P49             I/C resulted in high VEGF expression along entire SC. No VEGF treatment impacted the disease course.                                                                                                                                  *LIX1^-/-^* cat          [@B36]           
  T/p: hMSCs into DT, TA, TB    LV-PGK1-VEGF-165, -BDNF, -GDNF, -IGF-1 or -GDNF/-VEGF-165 (*ex vivo*)      P90 (F)            VEGF-165 and GDNF preserved MNs, improved NMJ innervation, and extended survival in isolation, with additive improvements in NMJ innervation and survival when co-delivered.                                                          SOD1^G93A^ rat           [@B133]          
  I/T                           Pseudotyped scAAV9-CMV-VEGF-165                                            P90                Preserved MNs, improved motor function, reduced microgliosis, and extended survival.                                                                                                                                                  SOD1^G93A^ mouse         [@B291]          
  **Other**                                                                                                                                                                                                                                                                                                                                                                                                   
  I/M: DT, GC, TB               Ad-RSV-NT-3 alone or with -CNTF                                            P3--5              NT3 improved motor function, reduced axonal degeneration, induced muscle re-innervation, and extended survival. CNTF addition provided additive effects.                                                                              *pmn* mouse              [@B97], [@B98]   
  I/S: lumbar                   rAAV-CMV-Bcl-2                                                             P35                Bcl-2 delayed disease onset, preserved MNs, and improved CMAP.                                                                                                                                                                        SOD1^G93A^ mouse         [@B12]           
  I/M: DT, GC, TB               Ad-RSV-CT-1                                                                P3--5              CT-1 delayed disease onset, weight loss, CMAP decline, and axonal degeneration, improved motor function and muscle weight, and extended survival.                                                                                     SOD1^G93A^ mouse         [@B30]           
  I/S: lumbar, or I/M: DT, GC   rAAV1/2-CBA-G-CSF                                                          P70 (F)            I/C delayed disease onset, preserved MNs and NMJs, improved motor function and axon regeneration post-nerve crush, and extended survival. I/M increased plasma G-CSF levels, but failed to transduce MNs.                             SOD1^G93A^ mouse         [@B105]          
  I/M: D, F, HL, InC, T         AAV6-CMV-PRDX3, or -NRF2                                                   P29--31            Neither PRDX3 or NRF2 impacted disease. Poor CNS transduction may have been the cause.                                                                                                                                                SOD1^G93A^ mouse         [@B186]          
  I/S: lumbar                   rAAV2/1-CAG-IL-10                                                          P1                 IL-10 did not impact disease onset, but extended survival. Altered immune system genes in CNS at end-stage.                                                                                                                           SOD1^G93A^ mouse         [@B11]           
  I/C and I/M: GC               LV-CMV-EEAT2, -GDH2, and/or -NRF2                                          P65                Individual EAAT2, GDH2, and NRF2 treatments all preserved MNs, but combination therapy also delayed disease onset, improved motor function and body weight, and extended survival.                                                    SOD1^G93A^ mouse         [@B24]           
  I/M: GC                       AAV1-CMV-NRG1                                                              P56/P84            NRG1 improved GC but not TA CMAP, preserved NMJs, but not axons or MNs, and increased collateral NMJ sprouting. Had no impact on motor function or disease onset. Effects were reduced when treated later.                            SOD1^G93A^ mouse         [@B163]          
  I/V: tail                     AAV9-CMV-DOK7                                                              P90 (M)            DOK7 increased NMJ size and innervation, reduced muscle atrophy, and extended survival, without preserving MNs.                                                                                                                       SOD1^G93A^ mouse         [@B175]          
  I/T                           ssAAV9-CMV-DAO                                                             P90                \>2-fold increase in lumbar SC DAO levels. Preserved MNs and axons, reduced microgliosis, and delayed muscle atrophy. Extended survival of F.                                                                                         SOD1^G93A^ mouse         [@B289]          

In the

Delivery

column, the mode of delivery (hMSC, human mesenchymal stem cell; hNPC, human neural progenitor cell; I/C, intracerebral; I/CV, intracerbroventricular; I/M, intramuscular; I/S, intraspinal; I/T, intrathecal; I/V, intravenous; MPC, muscle progenitor cell; SC, spinal cord; T/p, transplant) is followed by details of site of injection (Ab, abdominal; D, diaphragm; DT, dorsal trunk; F, facial; FL, forelimb; GC, gastrocnemius; HL, hindlimb; InC, intercostal; Ma, masseter; PS, paraspinal; Q, quadriceps; T, tongue; TA, tibialis anterior; TB, triceps brachii). In the

Virus-promoter-transgene

column, information on the viral vector (Ad, adenovirus; AAV, adeno-associated virus; EIAV, Rabies-G pseudotyped lentiviral-vector; LV, lentivirus; r, recombinant; Rv, retrovirus; sc, self-complementary; ss, single-stranded), gene promoter (CAG, hybrid cytomegalovirus enhancer/chicken β-actin; CBA, chicken β-actin; CMV, cytomegalovirus; PGK1, phosphoglycerate kinase 1; RSV, rous sarcoma virus; VSV-G, Vesicular Stomatitis Virus glycoprotein), and gene of interest (αCAR, coxsackievirus and adenovirus receptor; BDNF, brain-derived neurotrophic factor; Bcl-2, B-cell lymphoma-2; CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; DAO,

D

-amino acid oxidase; DOK7, docking protein 7; EAAT2, excitatory amino acid transporter 2; G-CSF, granulocyte-colony stimulating factor; GDH2, glutamate-dehydrogenase 2; GDNF, glial-derived neurotrophic factor; IGF-1/2, insulin-like growth factor 1/2; IL-10, interleukin-10; NRF2, nuclear factor erythroid 2-related factor 2; NRG1, Neuroregulin-1; NT-3, neurotrophin-3; PRDX3, peroxiredoxin 3; VEGF, vascular endothelial growth factor) is provided. Acronyms used in additional columns: ChAT, choline acetyltransferase; CMAP, compound muscle action potential; CNS, central nervous system;

LIX

,

limb-expression 1

; F, females only; M, males only; MN, motor neuron; NMJ, neuromuscular junction; P, postnatal day;

pmn

, progressive motor neuronopathy; SOD1, superoxide dismutase 1

.

Without detailed knowledge of disease etiology and underlying cellular pathologies, neuroprotection is potentially the only viable method for tackling a complex syndrome like ALS. However, with increased understanding of gain- and loss-of-function mechanisms of genetic forms of ALS, a second category of knockdown gene therapies encompassing ASOs and RNAi has emerged. These have principally been tested in SOD1, but also C9ORF72, rodent models (**Table [2](#T2){ref-type="table"}**). These oligonucleotide-mediated therapeutics are designed to specifically target and reduce levels of toxic, mutant proteins (e.g., C9ORF72, SOD1, TDP-43, FUS) and are showing promise in mice. While they may have a narrow applicability window due to small percentages of genetically determined ALS, given pathological commonalities, such as cytoplasmic TDP-43 sequestration ([@B189]) and possible involvement of wild-type SOD1 misfolding in disease ([@B32]), there is scope for broader application. Moreover, many sALS patients possess mutations in genes linked to fALS. Targeting the cause of disease in this manner is likely to have the greatest therapeutic impact, and obviates the requirement for co-treatment of multiple downstream pathways. The ASO IONIS-SOD1~Rx~ (a.k.a. ISIS 333611 and BIIB067) targets both wild-type and mutant SOD1 mRNA for degradation (**Figure [2B](#F2){ref-type="fig"}**). Importantly for this strategy, *Sod1* knockout mice develop normally and do not show motor neuron loss, although their response to axonal injury is impaired ([@B214]), and there is evidence that SOD1 loss-of-function may modify ALS severity ([@B229]). IONIS-SOD1~Rx~ administration into CSF of SOD1^G93A^ rats resulted in reduced SOD1 protein in spinal cord ([@B292]). IONIS-SOD1~Rx~ was thus tested in 24 ALS patients in a randomized, placebo-controlled phase I trial ([@B172]). In this first-in-human clinical study of intrathecal ASO delivery, ≈12 h infusion of IONIS-SOD1~Rx~ was shown to be safe and well tolerated. A phase Ib/IIa trial (NCT02623699) is currently recruiting ALS patients to further evaluate safety, tolerability, and pharmacokinetics of IONIS-SOD1~Rx~.

###### 

Knockdown strategy gene therapies tested in animal models of ALS.

  Delivery                                                                                        Therapeutic                                                 Targeted gene   Treatment age         Major findings                                                                                                                                                                                                                                                                                                                                                                                                               Animal model                                Reference
  ----------------------------------------------------------------------------------------------- ----------------------------------------------------------- --------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- -----------
  Repeated I/P                                                                                    ASO                                                         *p75^NTR^*      Starting at P60 (F)   p75^NTR^ levels reduced in lumbar SC, kidneys, and MNs. Delayed disease onset and extended survival, but did not impact disease progression.                                                                                                                                                                                                                                                                                 SOD1^G93A^ mouse                            [@B269]
  Repeated I/P                                                                                    ASO                                                         *GluR3*         Starting at P50       Delayed disease onset and extended survival, despite lack of GluR3 reduction in the lumbar SC.                                                                                                                                                                                                                                                                                                                               SOD1^G93A^ mouse                            [@B216]
  I/M: HL                                                                                         AAV2-CMV-siRNA                                              *SOD1*          P45                   SOD1 levels reduced in MNs, and motor function improved.                                                                                                                                                                                                                                                                                                                                                                     SOD1^G93A^ mouse                            [@B171]
  I/M: D, F, HL, InC, T                                                                           LV(EIAV)-CMV-shRNA                                          *SOD1*          P7                    SOD1 levels reduced in MNs. Delayed disease onset, preserved MNs, improved motor function, and extended survival.                                                                                                                                                                                                                                                                                                            SOD1^G93A^ mouse                            [@B211]
  I/S: lumbar                                                                                     LV-PGK1-shRNA                                               *SOD1*          P40                   SOD1 levels reduced in MNs and glial cells. Delayed disease onset, preserved MNs and axons, and improved motor function and CMAP.                                                                                                                                                                                                                                                                                            SOD1^G93A^ mouse                            [@B213]
  Repeated I/P, or continuous I/CV inf.                                                           ASO                                                         *SOD1*          P65                   SOD1 levels reduced in brain and SC by I/CV infusion. Slowed disease progression and extended survival, but did not affect disease onset.                                                                                                                                                                                                                                                                                    SOD1^G93A^ rat                              [@B245]
  Continuous I/T inf.                                                                             siRNA                                                       *FasR*          P90                   FasR levels reduced in SC. Preserved MNs and axons, improved motor function, and extended survival.                                                                                                                                                                                                                                                                                                                          SOD1^G93A^ mouse                            [@B153]
  I/M: GC, or I/V: tail                                                                           rAAV6-H1-shRNA                                              *SOD1*          P42                   I/M delivery targeted MNs and reduced SOD1 mRNA/protein in GC. I/V delivery reduced SOD1 levels in muscle, heart, and liver, and to a lesser extent in SC, but not brain. Disease onset and progression unaffected.                                                                                                                                                                                                          SOD1^G93A^ mouse                            [@B263]
  Continuous I/T inf.                                                                             siRNA                                                       *SOD1*          ≈P85 (M)              SOD1 levels reduced in SC. Delayed disease onset and extended survival.                                                                                                                                                                                                                                                                                                                                                      SOD1^G93A^ mouse                            [@B284]
  SN, or I/M: GC                                                                                  rAd-, or AAV2-U6-shRNA                                      *SOD1*          P94                   Nerve injection more efficient than I/M at MN delivery. rAd reduced SOD1 levels in MNs, slowed disease progression, and extended survival. rAAV2 did not confer any benefit.                                                                                                                                                                                                                                                 SOD1^G93A^ mouse                            [@B295]
  I/M: F, FL, HL, InC, T, TC                                                                      rAAV6-H1-shRNA                                              *SOD1*          P1/P5/P15             SOD1 levels reduced in muscles and MNs. Preserved MNs, NMJs, and axon, reduced muscle atrophy, but did not impact neuroinflammation or disease progression.                                                                                                                                                                                                                                                                  SOD1^G93A^ mouse                            [@B264]
  I/V: tail (P21), or temporal (P1)                                                               AAV9-CAG-shRNA                                              *SOD1*          P1- 2/P21/P85         P1 injections caused greater reduction than P21 in SOD1 levels in SC, due to more efficient MN transduction. Injections at all ages improved motor function, increased muscle mass, and extended survival, but only P1 delayed disease onset.                                                                                                                                                                                SOD1^G93A^ mouse; SOD1^G37R^ mouse          [@B76]
  Repeated I/P                                                                                    ASO                                                         *AChE*          P35/P84               Treatment at P35 preserved MNs and extended survival, but later delivery had no impact.                                                                                                                                                                                                                                                                                                                                      SOD1^G93A^ mouse                            [@B92]
  I/CV: continuous inf.                                                                           ASO                                                         *miR-155*       P60                   ASO incorporated into brain and SC, and miR-155 target genes impacted. Disease progression slowed and survival extended, but disease onset unaffected.                                                                                                                                                                                                                                                                       SOD1^G93A^ mouse                            [@B131]
  I/T                                                                                             AAV2/1-CMV-scFvD3H5                                         *SOD1*          P45                   Sustained expression was observed in MNs. Delayed disease onset, preserved MNs and axons, improved motor function, reduced                                                                                                                                                                                                                                                                                                   SOD1^G93A^ mouse                            [@B201]
  I/C                                                                                             AAV9-H1-shRNA                                               *SOD1*          P70                   SOD1 levels reduced in cortex, but not MNs. Delayed disease onset, preserved MNs and NMJs, improved motor function in hindlimbs, and extended survival.                                                                                                                                                                                                                                                                      SOD1^G93A^ rat                              [@B258]
  I/T                                                                                             rAAVrh10-CAG-amiR                                           *SOD1*          P55--60 (F)           SOD1 levels reduced in SC and MNs. Slowed disease progression and extended survival, but disease onset unaffected.                                                                                                                                                                                                                                                                                                           SOD1^G93A^ mouse                            [@B285]
  I/M: GC (P2), or I/CV (P2), or I/T (P35)                                                        AAV6-CMV-miR, and/or AAV9-gfaABC~1~D-miR, or AAV9-CMV-miR   *SOD1*          P2/P35                I/M (AAV6) delivery reduced SOD1 levels in GC. I/CV delivery resulted in MN (AAV6) and astrocyte (AAV9-gfaABC~1~D) targeting. Both I/CV treatments preserved MNs, and NMJs, improved motor function, decreased muscle atrophy, and extended survival. There was no additive effect. I/T (gfaABC~1~D and CMV) at P35 improved CMAP and motor function, but only CMV preserved MNs and NMJs. Survival was unaffected by I/T.   SOD1^G93A^ mouse                            [@B56]
  I/V: tail                                                                                       rAAVrh10-U6-miR, or CBA-miR                                 *SOD1*          P50-68                U6 delayed disease onset and extended survival, while CBA delayed disease progression and extended survival. The effects of U6 were marginally better than CBA. U6 also preserved MNs and improved motor function.                                                                                                                                                                                                           SOD1^G93A^ mouse                            [@B31]
  I/CV                                                                                            ASO                                                         *C90RF7 2*      ≈P90/≈P180            Different ASOs decreased repeat-containing C9ORF72 RNA levels in cortex and SC, sense foci in cortex, and poly(GP) and poly(GA) peptides at both time points. Behavioral deficits were alleviated when treated at ≈P180.                                                                                                                                                                                                     *C9ORF72* BAC transgenic mouse (C9^405B^)   [@B121]
  I/CV (P0), or I/P (P0, P3, and P6), or I/CV and I/V (P85)                                       MO                                                          *S0D1*          P0/P3/P6/ P85         SOD1 levels reduced in CNS via all routes. I/CV and I/V combination preserved MNs and axons, improved motor function, reduced microgliosis, and extended survival.                                                                                                                                                                                                                                                           SOD1^G93A^ mouse                            [@B192]
  I/CV                                                                                            AAV9-CAG-amiR                                               *S0D1*          P1                    *SOD1* mRNA levels reduced in CNS, muscle, and heart. Preserved MNs, NMJs and axons, delayed SC inflammation, improved motor function and extended survival.                                                                                                                                                                                                                                                                 SOD1^G93A^ mouse                            [@B248]
  I/CV                                                                                            ASO                                                         *Atxn2*         P1                    *Atxn2*, but not *TDP-43*, mRNA levels reduced in brain. Improved motor function and extended survival.                                                                                                                                                                                                                                                                                                                      *TDP-43^Tg/Tg^* mouse                       [@B21]
  I/CV and I/V: temporal (P1), or I/CV and I/V: temporal and/or RbS (P50), or I/S: lumbar (P50)   scAAVrh10-U7-ASO                                            *S0D1*          P1/P50                All paradigms reduced SOD1 levels in SC. Delayed disease onset and progression, improved motor function, and extended survival at both time points. Neonatal delivery preserved MNs, NMJs, and myofibres, and reduced microgliosis.                                                                                                                                                                                          SOD1^G93A^ mouse                            [@B26]
  I/V: tail (P21), or temporal (P1)                                                               scAAV9-CAG-shRNA                                            *S0D1*          P1/P21                Greater MN transduction at P1, shifting to astrocyte tropism at P21, with both reducing SOD1 levels in SC. Both treatments delayed disease onset, improved motor function, and extended survival, but amelioration was better at P1. Genetic suppression of NF-κB in microglia resulted in additive phenotypic improvements.                                                                                                 SOD1^G93A^ mouse                            [@B78]
  I/T                                                                                             rAAVrh10-CAG-amiR                                           *S0D1*          P30                   Slow and fast injection protocols resulted in different transduction patterns. Both protocols preserved axons, delayed disease onset, and extended survival. Slow injection produced greater phenotypic improvements.                                                                                                                                                                                                        SOD1^G93A^ mouse                            [@B146]

In the

Delivery

column, the mode of delivery (I/C, intracerebral; I/CV, intracerbroventricular; I/M, intramuscular; I/P, intraperitoneal; I/S, intraspinal; I/T, intrathecal; I/V, intravenous; SN, sciatic nerve) is followed by details of site of injection (D, diaphragm; F, facial; FL, forelimb; GC, gastrocnemius; HL, hindlimb; InC, intercostal; inf., infusion; P, postnatal day; RbS, retrobulbar sinus; T, tongue; TC, thoracic cavity). In the

Therapeutic

column, information on the type of therapeutic is provided (Ad, adenovirus; AAV, adeno-associated virus; amiR, artificial microRNA; ASO, antisense oligonucleotide; EIAV, Rabies-G pseudotyped lentiviral-vector; LV, lentivirus; miR, microRNA; MO, morpholino oligonucleotide; r, recombinant; sc, self-complementary; scFvD3H5, a secretable single-chain fragment variable (scFv) antibody composed of heavy and light chain regions of D3H5 monoclonal antibody that binds specifically to misfolded SOD1; shRNA, short hairpin RNA; siRNA, small interfering RNA; ss, single-stranded), along with details on promoter usage (CAG, hybrid cytomegalovirus enhancer/chicken β-actin; CBA, chicken β-actin; CMV, cytomegalovirus; gfaABC

1

D, minimal glial fibrillary acidic protein; H1, H1 RNA polymerase III; PGK1, phosphoglycerate kinase 1). Additional acronyms used in other columns include: AChE, acetylcholinesterase; Atxn2, ataxin-2; BAC, bacterial artificial chromosome; CMAP, compound muscle action potential; F, females only; FasR, Fas receptor; GluR3, glutamate receptor subunit 3; M, males only; MN, motor neuron; NMJ, neuromuscular junction; p75

NTR

, p75-neurotrophin receptor; SC, spinal cord; SOD1, superoxide dismutase 1; Tg, transgene

.

SMA Gene Therapy Lessons for ALS
================================

There are numerous possible intersecting explanations for the plethora of failed ALS clinical trials ([@B174]), not limited to (1) most pre-clinical research has been conducted in SOD1^G93A^ mice, which do not accurately model the entire ALS spectrum; (2) poor experimental design and execution of pre-clinical work ([@B234]); (3) focusing on mouse survival as an indicator of drug potential ([@B85]); (4) pharmacological issues such as insufficient dose or access/bioavailability to targeted tissue; (5) timing of intervention ([@B23]); (6) patient heterogeneity, poor trial stratification, and scarcity of biomarkers; and (7) incomplete understanding of disease mechanism(s).

Similar difficulties have, at least partially, been overcome by the SMA research community in order for nusinersen to receive regulatory approval. Being a monogenic condition, treating SMA is undoubtedly simpler than the challenge posed by the broad-ranging heterogeneity of ALS. Nonetheless, the clinical approval of nusinersen was a significant milestone not just for SMA, but gene therapy as a whole. That is not to say that the job is complete for SMA, as the clinical response to nusinersen is wide-ranging and includes non-responders ([@B71]). However, over the last decade, a great deal has been learnt from the pre-clinical development of SMA gene therapies and the clinical trials of nusinersen and AVXS-101. Given the clinical and mechanistic overlap between the diseases, these lessons learned from SMA may be useful for ALS, particularly when considering the array of gene therapies pre-clinically tested in ALS rodent models (**Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**) and thus likely to be in the clinical drug pipeline. We have therefore summarised this information to emphasize some key points for ALS gene therapy development.

Careful Therapeutic Targeting Is Required
-----------------------------------------

A clear understanding of where a therapy is needed is mandatory for clinical success. SMA is primarily a LMN disorder; however, in severe cases, pervasive pathology has been reported. For instance, congenital heart problems ([@B228]), bone complications ([@B128]), and vascular defects ([@B246]) are known to occur in some type I SMA patients. Cell intrinsic SMN depletion causes similar and additional pathologies in mice ([@B100]). A sliding scale of vulnerability to SMN reduction has therefore been suggested; at one end, LMNs are the first cell type disturbed by diminished SMN, and as levels are decreased further, more cell types and tissues become affected ([@B243]). This appears to be the case in mouse models, but may be sub-clinical in the majority of SMA patients, as non-motor neuronal involvement is less common. Nevertheless, concerns persist that treating SMA patients with nusinersen, which is delivered directly to the CSF to target LMNs, may alter disease trajectory and reveal novel pathologies caused by chronic SMN deficiency outside the CNS ([@B260]).

There is thus discussion, for both ASOs and viruses, as to which single delivery route provides the best therapeutic outcome for SMA ([@B112]; [@B89]; [@B208]; [@B193]; [@B302]). Major determinants of this are the BBB and the BSCB, which not only restrict access of systemically delivered therapies to the brain and spinal cord, but can also confine drugs within the CNS when directly administered. Targeting therapies to NMJs for uptake and retrograde transport along motor axons can circumvent these barriers ([@B261]; [@B178]; [@B262]), but this is compromised by denervation. Nonetheless, once inside the CNS, ASOs are able to distribute widely ([@B219]). Accordingly, intracerebroventricular injection of SMN ASOs results in robust SMN upregulation in the CNS ([@B111]; [@B199]; [@B208]; [@B219]), while intravenous or subcutaneous administration triggers a more systemic increase outside the CNS ([@B112]; [@B127]). Viral vectors are better than ASOs at overcoming BBB permeability problems ([@B77]; [@B273]; [@B59]; [@B169]), but distinctions in therapeutic outcome between routes still apply ([@B88],[@B89]). In addition, modifying the delivery speed of intrathecal injections can alter AAV tropism; slower injections (i.e., over 8 min) result in preferential transduction of the spinal cord, whereas faster injections (i.e., over 30 s) preferably transduce the brain and peripheral tissue ([@B146]). Notwithstanding, there remains little doubt that using multiple injection modes to provide body-wide SMN augmentation provides the best phenotypic rescue in SMA mice ([@B193]; [@B196]), while limiting the onset of delayed, non-neuronal pathologies such as tail necrosis ([@B77]; [@B59]). The importance of careful therapeutic targeting of SMN to all required cells has been confirmed using numerous transgenic mice where SMN has been overexpressed in SMA models in a tissue-specific fashion ([@B91]; [@B166]).

Cautious selection of administration route is not the only way to affect the voyage of gene therapy through the body. A number of additional therapy-dependent tactics can be employed to optimize delivery. Despite limited packaging capacity (≈4.5 kb for single-stranded and ≈2.4 kb for self-complementary AAV), AAV has become the most promising vector for gene delivery in neurological disease; it establishes stable nuclear episomes, thus reducing the risk of integrating into the host genome and causing insertional mutagenesis, it can transduce both dividing and non-mitotic cells, and it maintains exogenous gene expression for extended periods ([@B185]). With approximately twice the capacity of AAV, LV has also been employed as a proof-of-concept vector in pre-clinical models of SMA ([@B13]) and ALS (**Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**); however, given that LV can randomly insert into the host genome, there are major safety issues associated with its clinical application ([@B117]). The advantages of AAV led to scAAV9 being chosen for *SMN1* delivery in the AveXis gene therapy, AVXS-101. AAV serotypes possess divergent capsid proteins that bind to distinct host cell surface receptors and co-receptors, thereby determining the cells a virus can transduce (i.e., the tropism) and how efficiently it can spread ([@B185]). Multiple AAV serotypes have been used in SMA mice ([@B77]; [@B200]; [@B265]), but serotype 9 was selected for AVXS-101 because of its comparatively strong tropism toward LMNs throughout the spinal cord in a range of species ([@B75]; [@B25]; [@B67]). While numerous AAV serotypes and administration routes have also been tested in ALS mice (**Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**), it remains unclear which serotype will prove to be most effective. AAV9 and AAVrh10 are good candidates, but natural and engineered serotypes have recently been identified with improved tropism toward ALS-pertinent tissues ([@B55]; [@B42]). Viral transgene expression can also be restricted using promoters with selective and defined expression patterns ([@B135]). Combining knowledge of viral tropism with promoter selectivity thus provides a potential method for exquisite, cell type-specific targeting ([@B283]). Disease state ([@B44]) and age ([@B75]; [@B262]) also impact viral tropism, likely through alterations in host cell receptor availability, while promoter usage likewise changes with pathology and time; hence, it will be vital to test permutations of virus serotype/promoter in relevant pre-clinical models of ALS throughout all stages of disease.

Unlike AAV, ASOs do not readily penetrate tissues, while their cellular uptake and transition to the nucleus, their site of action, is limited. Indeed, it is estimated that \<1% of ASOs reach their desired target, as the majority distribute to unwanted organs such as the liver ([@B90]). This mandates repeated therapeutic injections that can cause adverse events ([@B99]) and toxic ASO accumulation ([@B90]). Consequently, several chemical modifications to the ASO phosphate backbone have been tested and shown to improve safety and pharmacological properties ([@B64]). Moreover, a number of drug distribution systems compatible with systemic delivery are being developed that enhance ASO transport to disease-pertinent tissues and therefore ease administration and reduce the required dose. These ASO vectorisation strategies can be divided into (1) viral approaches that use harmless, non-replicating viruses, such as AAV, and (2) non-viral strategies that utilise different positively charged molecules such as lipids or peptides ([@B144]). Viruses present immunogenicity issues and are not suitable for all nucleic acid-based molecules; nevertheless, to aid cellular targeting and cytoplasm-to-nucleus transport, viral vectors have been engineered to encode modified snRNAs that incorporate specific ASO sequences. Once inside target cells, these ASOs are imported into the nucleus where they accumulate as part of snRNPs ([@B117]). When packaged into viral vectors, snRNAs containing ASOs targeting *SMN2* have shown potential for SMA ([@B170]; [@B52]; [@B194]). As has the non-viral approach of conjugating ASOs to CPPs ([@B101]; [@B235]). CPPs are 5--30 amino acid long, positively charged peptides that transport various macromolecules across cell membranes ([@B144]). Highlighting the significance of therapeutic targeting, intravenous injection of an *SMN2* SSO conjugated to a CNS-targeting CPP caused the greatest extension in SMA mouse survival reported to date -- from 12 to 456 days compared to only 54 days for the "naked" oligonucleotide ([@B101]). Importantly, these CPP-oligonucleotides are capable of delivery to the CNS of both neonatal and adult mice ([@B101]; [@B235]); however, the safety, tolerability, and pharmacokinetics of CPP-conjugated ASOs are yet to be tested in additional organisms.

AAV and LV have separately been combined with RNAi-based strategies for SOD1 knockdown (**Table [2](#T2){ref-type="table"}**), but only recently have ASO vectorisation strategies been tried in ALS models. Compared with non-encapsulated oligonucleotides, loading *SOD1*-specific ASOs into lipid particles caused a much greater reduction in SOD1 protein in HEK293 cells ([@B43]). Moreover, direct intravascular delivery of non-ASO-loaded nanoparticles resulted in brain accumulation in wild-type zebrafish, indicating promise for future work in ALS mice ([@B43]). *SOD1* pre-mRNA-targeting ASOs were also embedded in modified snRNAs and engineered into AAVrh10, which was then co-injected into the blood and brain of SOD1^G93A^ mice either at birth or pre-symptomatically at 50 days ([@B26]). The ASO skips *SOD1* exon 2 generating a premature stop codon, which resulted in ≈70% reduction of SOD1 protein levels in the spinal cord 112 days post-perinatal administration. The gene therapy caused vast improvements in neuromuscular function, restricted weight loss, and, when given early, resulted in the greatest SOD1^G93A^ survival extension yet reported to ≈250 days ([@B26]).

Amyotrophic lateral sclerosis patients and models do not show the same cell and tissue vulnerability-resistance continuum as SMA; however, it is clear that pathology is not limited to LMNs and UMNs, probably contributing to the gamut of unsuccessful ALS clinical trials ([@B15]). Indeed, the ALS/FTD clinicopathological overlap ([@B182]; [@B189]; [@B278]) has been replicated in ALS mice, indicating the importance of cortical cells and synapses to the disease ([@B74], [@B73]). Furthermore, the non-cell autonomous toxicities emanating from cells such as microglia ([@B210]), and the prion-like cell-to-cell spread of pathological aggregates, also indicate that targeting therapies to motor neurons as well as additional cells and tissues is likely to be required in order to generate meaningful improvements in ALS prognosis. Indeed, disease onset and mortality are delayed in mutant SOD1 mice when microglial activation is pharmacologically restricted prior to disease onset ([@B134]; [@B275]), while disease progression is slowed in mutant SOD1 mice in which SOD1 is removed from microglia, oligodendrocytes, or astrocytes ([@B29]; [@B296]; [@B122]). Moreover, expression of mutant SOD1 in motor neurons alone is insufficient to fully recapitulate the mutant SOD1 mouse phenotype ([@B149]; [@B209]), while deletion of *SOD1* from motor neurons and interneurons of SOD1 mutant mice only delays disease onset ([@B288]).

Spinal muscular atrophy research has highlighted the importance of comparing different therapy injection sites and testing novel technologies to improve targeting of therapeutics not only to the required tissues, but also to the correct resident cells and subcellular locations. Viral targeting of rapidly dividing cells affected by ALS (e.g., astrocytes), subtleties in motor neuron subtype vulnerability ([@B190]), along with the indication that different subcellular motor neuron compartments, such as the NMJ, may require differential support and treatment ([@B179]), add to the complexity of the challenge ahead. It is therefore imperative that during ALS therapy design, careful consideration is given to what cells and tissues need to be targeted and how exactly this can be most effectively achieved.

Combinatorial Treatment Is Key
------------------------------

It is conceivable that carefully crafted gene therapy combinations targeting multiple disease mechanisms could provide additive effects in MNDs. Indeed, AAV1-follistatin treatment significantly boosted muscle and body weight of SMA mice suboptimally dosed with *SMN2* ASO ([@B69]), while in isolation, follistatin upregulation or myostatin reduction have little effect ([@B252]; [@B220]). Co-delivery of recombinant follistatin with an *SMN2*-inducing compound also resulted in a small additive enhancement in motor function, but not survival ([@B104]). Similarly, genetic upregulation of SMA modifier plastin 3 has no effect on untreated SMA mouse lifespan ([@B2]), but can drastically improve survival in ASO-dosed animals ([@B108]). A range of other pathological mechanisms could be concomitantly targeted in SMA ([@B33]). Combinations of drugs directed at just the SMN pathway have also proven more effective than individual treatments ([@B137]; [@B150]), while the impact of ASOs targeting *SMN2* has been enhanced by co-treatment with a compound ([@B197]), co-targeting the *SMN2*-repressing long non-coding RNA, *SMN-AS1*, for ASO-mediated knockdown ([@B62]; [@B293]), and co-masking additional negative *SMN2* splicing elements ([@B198]). Furthermore, a holistic approach to treatment appears to be important, as providing nutritional support to SMA mice can advance therapeutic efficacy ([@B187]; [@B38]).

These SMA studies suggest that previously unsuccessful therapeutics may provide additive benefits when used in combination, highlighting the importance of simultaneously treating multiple disease pathways. Given the pathology observed in ALS, it will also be vital to co-modify pathways in different cell types. To facilitate this, viral vectors engineered with selective promoters could be united with CPP-conjugated ASOs in order to synergistically target multiple genes in related and independent pathways across distinct and highly specific cell populations. This was recently confirmed in mutant SOD1^G93A^ mice by concomitantly targeting distinct disease mechanisms in motor neurons, astrocytes and microglia ([@B78]). In isolation, genetic suppression of the NF-κB pathway in microglia or shRNA-mediated knockdown of *SOD1* in motor neurons and astrocytes via systemic AAV9 administration resulted in similar improvements in survival, disease onset, and progression of mutant SOD1 mice. However, the combined targeting of these two pathomechanisms across three major cell types resulted in an additive amelioration in all assessed phenotypes. The median mutant lifespan was expanded from 137 to 188 days with a maximum survival of 204 days, which is one of the best extensions reported to date ([@B78]). In a separate study, joint lentiviral targeting of three distinct disease pathways aiming to reduce excitotoxicity resulted in a synergistic neuroprotective effect in SOD1^G93A^ mice ([@B24]), while simultaneous delivery of multiple neurotrophic factors can also induce modest additive effects over individual therapies ([@B97]; [@B133]; [@B51]), although not consistently ([@B58]). Like SMA, it is thus clear that prognosis can be improved in ALS models by attempting a multifaceted gene therapy approach. It is somewhat surprising that there have not yet been any published studies that test concurrent delivery of neuroprotective and knockdown strategies *in vivo* for ALS. ASO-mediated depletion of toxic mutant proteins is likely to be most critical in ALS, and should be joined with a gamut of neuroprotective accessory therapies such as neurotrophic factors ([@B106]), SMN upregulation (e.g., via nusinersen or AVXS-101) ([@B124]; [@B268]), and preservation of NMJ innervation ([@B175]), in order to determine the most efficacious drug combinations.

Consider Dose Number and Drug Concentrations
--------------------------------------------

In addition to delivering gene therapies to the intended cellular and subcellular site(s), effectors must be expressed/released at a therapeutically viable concentration. Providing multiple *SMN2* ASO doses results in greater phenotypic amelioration in SMA mice ([@B112]; [@B302]; [@B101]), while increased concentrations of ASOs or AAVs have a similar positive effect ([@B169]; [@B101]; [@B108]). These results unsurprisingly indicate that delivering greater quantities of therapy, results in higher SMN upregulation, and therefore a better phenotypic rescue of SMA mice. There will inevitably be a point at which SMN overexpression becomes detrimental to cells; however, two-fold genetic overexpression of *SMN* in the nervous system of control mice appears to be safe ([@B268]; [@B205]). Nevertheless, this may not be the case for all genes ([@B54]), and thus care must be taken when artificially increasing protein abundance, especially considering that secreted proteins can elicit autocrine and paracrine effects ([@B20]).

Caution must also be exercised with target gene reduction strategies as there may be disparate, time-dependent consequences between protein reduction below a physiological threshold and complete absence ([@B226]). That being said, toxicities associated with ASO or AAV accumulation are likely to arise before viability is perturbed by excessive modulation of a gene. Hence, there is a fine balance between administering sufficient gene therapy to ensure correct targeting in effective quantities without causing systemic toxic accumulation and adverse side effects. Upon intravenous injection, ASOs accumulate in the liver, kidneys, and lymph nodes, amongst other places, and can cause hybridisation-independent toxicities ([@B90]), while AAVs can become similarly enriched ([@B304]). The methods to enhance delivery to disease-susceptible cells and tissues discussed above (e.g., ASO-CPP conjugation) will undoubtedly aid in this battle, and should be optimized in ALS mice, along with ASO chemistries, to enrich the appropriately targeted therapeutic load. Moreover, multiple ASO doses and increasing concentrations of gene therapies must be tested in relevant models to identify the most effective and safe therapeutic regimes. Due to the immune response, repeated AAV dosing is not practical (although immunomodulation is an option) ([@B154]), but ASOs can be administered at multiple time points. However, ASO concentration must also be optimized to escape host immune responses ([@B284]). It should also be remembered that once an AAV has been delivered, relatively little can be done to regulate transgene expression, but ASOs can be neutralized by sequestration using complimentary decoy ASOs ([@B219]; [@B110]).

Therapeutic Timing Is Critical
------------------------------

As disease progresses, the number of impacted proteins and processes will likely increase as a result of time as pathways diverge from the initial cause of pathology. This provides a rationale for why selectively targeting individual disease pathways toward the end of a cascade may provide only limited benefit. Moreover, the greater the duration over which a disease develops, the more anatomical, circuit, and cellular damage will ensue leading to greater loss-of-function and thus a more significant challenge of recovery ([@B212]; [@B16]). For example, early NMJ denervation followed by LMN die-back will severely, if not totally, restrict the ability of the LMN to respond to extracellular neurotrophic signaling. The successful treatment of any disorder is thus more likely to occur when a therapy is administered during early pathogenesis rather than at later time points and, in particular, at disease end stage. Whilst intuitive, this highlights the importance of earlier diagnosis, especially for ALS.

Indeed, the earlier SMN levels are augmented in SMA mice via *SMN* gene therapy, the better the therapeutic outcome ([@B77]; [@B111], [@B112]; [@B208]; [@B28]; [@B302]). Age-dependent differences in BBB permeability, neuropil density, and cell tropisms may contribute ([@B75], [@B77]); however, the early temporal requirement for SMN has been corroborated using mice with inducible *SMN* alleles ([@B138]; [@B159]; [@B123]), and is consistent with human and mouse *SMN* being most highly expressed in the CNS perinatally ([@B120]), and the most common and severe form of SMA (type I) manifesting before 6 months of age. Accordingly, artificially reducing SMN levels in young adult mice has fewer repercussions than when SMN is diminished at earlier time points ([@B138]; [@B123]). All of this suggests that there is a therapeutic window of opportunity during early development in which *SMN* gene therapy is likely to have the greatest chance of success. One study indicates that in mice, the postnatal window of highest SMN requirement coincides with neuromuscular maturation, and that NMJ disruption causes SMN upregulation in motor neurons ([@B123]). Accordingly, nusinersen is being tested in the open-label NURTURE trial in pre-symptomatic newborns genetically diagnosed with SMA. Interim analyses appear promising, and when complete are likely to provide compelling evidence of the importance of treating SMA as early as possible. It is perhaps for this reason, that a number of small molecule drugs that have proven useful in SMA mice dosed from birth, have failed in clinical trials in which patients are treated post-symptom onset ([@B82]). Nevertheless, post-symptomatic restoration of SMN using an inducible allele has been shown to reverse overt neuromuscular pathology and significantly improve SMA mouse lifespan ([@B159]). This was corroborated using systemic administration of *SMN2*-targeting ASOs in a mild SMA mouse model ([@B28]), and in SMA mice sub-optimally dosed with a small molecule *SMN2* splice-modifying drug and subsequently re-treated with the same compound or AAV1-follistatin gene therapy ([@B69]).

Early therapeutic interventions in mutant SOD1 mice also often result in greater impact on disease. For example, pre-symptomatic injection of VEGF-expressing LV into SOD1^G93A^ mouse muscles resulted in greater delay in disease onset and progression compared to injection at paralysis onset ([@B14]). The same is true for AAV-mediated IGF-1 delivery ([@B126]) and SOD1 silencing ([@B76]; [@B26]), and recombinant VEGF injections into the brain of mutant SOD1 rats ([@B249]). Significantly, these studies show, like in SMA, that survival of mutant SOD1 rodents can be extended even when therapies are delivered post-symptomatically. There is also evidence to indicate that treatment during the perinatal stage (e.g., postnatal day 1, P1) can cause even greater improvements in SOD1^G93A^ lifespan ([@B76]; [@B26]), perhaps due in part to sub-clinical embryonic/perinatal defects ([@B277]) and differential age-dependent gene therapy tropism ([@B75]); however, testing intervention timing in these models needs to be therapeutically appropriate, as ALS is an adult-onset neurodegenerative disease currently with no biomarkers. The pre-symptomatic treatment of fALS patients with a known ALS-causing genetic mutation is a possibility, in the same vein as SMA patients in the NURTURE trial of nusinersen, but treatment in humans at an age akin to P1 is highly unlikely. Nevertheless, perinatal therapy administration paradigms provide useful proof-of-concept information, and are invaluable in gene therapy optimisation.

Amyotrophic lateral sclerosis greatly impacts the neuro-muscular system and its proteome, which could cause disease-specific, time-constrained alterations that affect therapeutic efficacy; for instance, viral tropism could be impacted through differential receptor expression ([@B262]). Rodent work indicates that there is likely to be an optimal period for ALS therapy delivery, but with a broader therapeutic window, in which disease progression can at least be slowed, if not halted or even partially reversed. It is therefore paramount that potential therapeutics are tested at a range of time points in ALS rodents and in large animals including non-human primates in order to improve therapeutic timing strategy.

Conclusion
==========

Typified by extensive heterogeneity, the ALS disease spectrum poses a daunting challenge for developing effective treatments. This diversity, along with numerous other factors, has resulted in an overabundance of unsuccessful clinical trials. Many of these involved compounds targeting likely secondary pathogenic pathways with only limited therapeutic potential. However, over the last two decades, gene therapy using ASOs or viral vectors have emerged as the most promising strategy for treating nervous system disorders. The predominantly LMN disease SMA has benefited from this burgeoning field, with the recent regulatory approval of the ASO nusinersen. Through developing ASO- and virus-mediated drugs for SMA, much has been learnt about gene therapy design and development that could help to alleviate the impact of other MNDs. Pre-clinical SMA research has made it clear that gene therapies must be efficiently delivered to pertinent sites of pathology, at concentrations within the therapeutic range, and at appropriate times in order to increase the chances of success. Tantamount to this is the parallel modification of multiple disease pathways across cell and tissue types. Similar conclusions are also beginning to emerge from pre-clinical ALS models. It is thus by no coincidence that the greatest amelioration of the SOD1^G93A^ mouse phenotype to date was driven by the combined targeting of two pathomechanisms across multiple cell types, and the dual-administration of an AAV-guided *SOD1*-specific ASO into the blood and brain. Given the current lack of diagnostic and prognostic biomarkers for ALS and reliance upon the SOD1^G93A^ mouse, successful translation to patients will be tricky. Nevertheless, by considering issues outlined in this review and thinking clearly about treatment logistics, a viable ALS gene therapy is unlikely to be far from the clinic.
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:   adeno-associated virus
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ASO

:   antisense oligonucleotide

BBB

:   blood-brain barrier

BDNF

:   brain-derived neurotrophic factor
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:   blood-spinal cord barrier
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:   chromosome 9 open reading frame 72

CNS

:   central nervous system
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:   ciliary-derived neurotrophic factor
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:   cell-penetrating peptide

CSF

:   cerebrospinal fluid
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:   European Medicines Agency
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FDA
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FTD

:   frontotemporal dementia

FUS
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HGF

:   hepatocyte growth factor

IGF-1

:   insulin-like growth factor
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:   induced pluripotent stem cell
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LMN

:   lower motor neuron
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:   lentivirus

MND

:   motor neuron disease

NMJ

:   neuromuscular junction

RNAi

:   RNA interference
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:   sporadic ALS

scAAV

:   self-complementary AAV

SMA

:   spinal muscular atrophy

SMN

:   survival motor neuron

snRNA

:   small nuclear RNA

snRNP

:   small nuclear ribonucleoprotein

SOD1

:   superoxide dismutase 1

SSO

:   splice-switching oligonucleotide
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:   transactive-region DNA binding protein

TLS
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:   upper motor neuron

VEGF

:   vascular endothelial growth factor.
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